CTOs on the Move

Tishcon Corp

www.qgel.com

 
Tishcon Corp is a Salisbury, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.qgel.com
  • 820 Brown St
    Salisbury, MD USA 21804
  • Phone: 410.548.5011

Executives

Name Title Contact Details

Similar Companies

Xenocor

Bringing to market revolutionary laparoscopic technologies which extend the benefits of minimally invasive surgery to hundreds of millions of people worldwide.

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.

harris pharmaceutical

harris pharmaceutical is a Fort Myers, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Septodent

Septodent is a Cambridge, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.